The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.

The Centers for Disease Control and Prevention (CDC) published a page on Friday listing the conflicts of interest reported by ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

The FDA has approved Penmenvy, a vaccine for individuals aged 10 to 25, targeting five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which cause invasive meningococcal disease ...

Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug ...

The Centers for Disease Control and Prevention is tracking conflicts of interest that may exist for a key vaccine advisory committee. On Friday, the CDC published a page tracking projects expert ...

The CDC is planning a large study on potential vaccinAutism's links, despite extensive research dismissing any connection.

We welcome new tools to help protect more adolescents from meningococcal disease. Pentavalent MenABCWY vaccines could help address the disease by providing protection against the five vaccine ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.